Committee for Medicinal Products for Human Use (CHMP). Public assessment report enzalutamide. European Medicines Agency (EMA). 2013 and updates. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi. Accessed 16 Jul 2026.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.

Article  PubMed  PubMed Central  Google Scholar 

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.

Article  CAS  PubMed  Google Scholar 

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–31.

Article  CAS  PubMed  Google Scholar 

Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122–9.

Article  CAS  PubMed  Google Scholar 

Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poondru S, Ghicavii V, Khosravan R, Manchandani P, Heo N, Moy S, et al. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022;15(5):1131–222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerbershagen HJ, Ozgur E, Straub K, Dagtekin O, Gerbershagen K, Petzke F, et al. Prevalence, severity, and chronicity of pain and general health-related quality of life in patients with localized prostate cancer. Eur J Pain. 2008;12(3):339–50.

Article  PubMed  Google Scholar 

Walsh EA, Pedreira PB, Moreno PI, Popok PJ, Fox RS, Yanez B, et al. Pain, cancer-related distress, and physical and functional well-being among men with advanced prostate cancer. Support Care Cancer. 2022;31(1):28.

PubMed  PubMed Central  Google Scholar 

Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236–47.

Article  CAS  PubMed  Google Scholar 

Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl. 4):iv166–91.

Article  CAS  PubMed  Google Scholar 

Benoist GE, van Oort IM, Burger DM, Koch BCP, Mehra N, van Erp NP. The combination of enzalutamide and opioids: a painful pitfall? Eur Urol. 2019;75(2):351–2.

Article  PubMed  Google Scholar 

Detert Oude Weme SEH, Hulskotte LMG, Vervenne WL, Imholz ALT, Cremers R, Taxis K, et al. Enzalutamide reduces oxycodone exposure in men with prostate cancer. Clin Pharmacokinet. 2023;62(7):989–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27(1):1–5.

Article  PubMed  Google Scholar 

Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans. Clin Pharmacokinet. 1993;24(4):344–54.

Article  PubMed  Google Scholar 

Klimas R, Mikus G. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth. 2014;113(6):935–44.

Article  CAS  PubMed  Google Scholar 

Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005;25(5):521–44.

Article  CAS  PubMed  Google Scholar 

Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos. 2003;31(9):1086–9.

Article  CAS  PubMed  Google Scholar 

Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008;36(4):688–94.

Article  CAS  PubMed  Google Scholar 

Van Crugten JT, Sallustio BC, Nation RL, Somogyi AA. Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metab Dispos. 1991;19(6):1087–92.

Article  PubMed  Google Scholar 

Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol. 2000;55(10):713–9.

Article  CAS  PubMed  Google Scholar 

Binning AR, Przesmycki K, Sowinski P, Morrison LM, Smith TW, Marcus P, et al. A randomised controlled trial on the efficacy and side-effect profile (nausea/vomiting/sedation) of morphine-6-glucuronide versus morphine for post-operative pain relief after major abdominal surgery. Eur J Pain. 2011;15(4):402–8.

Article  CAS  PubMed  Google Scholar 

Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62(13):1238–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weiss J, Kocher J, Mueller C, Rosenzweig S, Theile D. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. Biopharm Drug Dispos. 2017;38(9):517–25.

Article  CAS  PubMed  Google Scholar 

Zheng T, Yin H, Shan H, Sun L, Jiang L, Liu Y. Synergistic inhibitory effects of enzalutamide and its phase I metabolite on UDP-glucuronosyltransferase 1A1 (UGT1A1) and risk prediction of drug-drug interactions. Chem Biol Interact. 2026;423:111829.

Article  CAS  PubMed  Google Scholar 

Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. European Medicines Agency (EMA). 2023. Available from: https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline. Accessed 3 Mar 2026.

Benoist GE, van der Meulen E, van Oort IM, Beumer JH, Somford DM, Schalken JA, et al. Development and validation of a bioanalytical method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma: application to clinical management of patients with metastatic castration-resistant prostate cancer. Ther Drug Monit. 2018;40(2):222–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Christrup LL, Sjogren P, Jensen NH, Banning AM, Elbaek K, Ersboll AK. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine? J Pain Symptom Manage. 1999;18(3):164–73.

Article  CAS  PubMed  Google Scholar 

Shargel L, Ducharme MP. Shargel and Yu's Applied biopharmaceutics and pharmacokinetics. 8th ed. McGraw Hill Education, New York, United States of America; 2022.

Committee for Medicinal Products for Human Use (CHMP). ICH M13A Guideline on bioequivalence for immediate-release solid oral dosage forms. 2025. Available from: https://www.ema.europa.eu/en/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-scientific-guideline. Accessed 25 Jul 2026.

U.S. Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available from: https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events. Accessed 20 July 2025